Tukey post-hoc analyses of statistically EPZ015666 significant interactions were used to determine SB525334 price treatment differences at an alpha level of P ≤ 0.05. Results We observed no significant differences for age (25.4 ± 6.6 y), BMI (25.2 ± 1.4 kg/m2), weight (72.9 ± 4.9 kg), or plasma lipids. We have presented the dietary characteristics of our study cohort in Table 1. Overall, we did not observe any statistical difference of the dietary macronutrient composition between treatment groups at baseline or following treatment with the exception of the N3 given to the treated participants. In comparison to reports on national averages, we observed no significant

differences between our current cohort and previous reports detailing the N3 intake of those individuals residing the United States. Table 1 Dietary characteristics of study participants   Placebo (n = 10) MicroN3 (n = 10)   Mean SE Mean SE Energy (MJ) 6.74 0.7 6.36 0.6 Protein (g) 73.2 4.4 68 4.4 Carbohydrate (g) 198.8 25.4 186.3 25.4 Total Fat (g) 72.1 4.8 65.1 4.8 Sat Fat (g) 19.5 2.0 18.2 2.0 MUFA (g) 22.9 2.3 21.2 2.3 PUFA (g) 14.9 1.7 11.5 1.7 α-Linoleic (g) 13.1 1.5 12.5 1.5 α-Linolenic (g) 1.4 0.2 1.3 0.2 Arachadonic (mg) 10.1 0.3 10.1 0.3 EPA (mg) 10.1 0.3 10.1 0.3 DHA (mg) 10.1 0.2 10.1 0.2 Cholesterol (mg) 215 37.5 202.9 37.5 Fiber (g) 18.7 3.5 16.7 3.5 Alcohol (g) 7.2 1.7 7.6 1.7 As part of their treatment, the MicroN3 treated group increased their buy NVP-HSP990 daily intake of EPA/DHA derived N3 by 450–550 mg/d. Following treatment with MicroN3 foods, our statistical analysis showed a significant elevation in mean plasma DHA (P < 0.05) and reduction in triacylglycerols within the treatment group (P < 0.05; Table 2). When expressed as mean

delta scores, both the increase in DHA and decrease in triacylglycerols were significantly different from placebo (P < 0.05). While plasma EPA showed a trend to increase in the treatment group, there was no statistical difference noted between the treatment and the placebo group (P = 0.08). Lastly, the results of our tertiary analysis showed no difference between either treatment group, nor no occurrence of questioned effects for any of our interview questions. In essence, our intervention Idoxuridine showed no occurrences of being able to identify MicroN3 foods via fish odor from food, gastrointestinal distress, fishy aftertaste or fish odor on the participant’s breath. Table 2 Lipid and plasma fatty acid characteristics of the study participants LIPID PROFILE Pre-treatment Post-treatment Total-C (mmol/L) Control 5.02 ± 0.2 5.06 ± 0.2   Treatment 4.22 ± 2.3 4.21 ± 2.2 LDL-C (mmol/L) Control 3.13 ± 0.2 3.10 ± 0.2   Treatment 2.42 ± 2.2 2.44 ± 2.3 HDL-C (mmol/L) Control 1.39 ± 0.1 1.46 ± 0.1   Treatment 1.34 ± 0.6 1.35 ± 0.7 VLDL-C (mmol/L) Control 0.